Tandem Diabetes Care has raised $120 million for its IPO, which rolled out on Thursday. The company is selling 8 million shares of its stock at a price of $15 per share. The stock is trading on the NASDAQ under the ticker symbol “TNDM.” Bank of America Merrill Lynch and Piper Jaffray are serving as lead underwriters. Based in San Diego, Tandem Diabetes Care is a provider of medical devices that treat diabetes. The firm is backed by Delphi Ventures, Domain Associates, TPG Biotechnology Partners, HLM Venture Partners and Kearny Venture Partners.
Tandem Diabetes Care®, Inc. (“Tandem”), a medical device company and manufacturer of the t:slim® Insulin Pump, today announced the pricing of its initial public offering of 8,000,000 shares of common stock at a price of $15.00 per share. In addition, Tandem has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares at the initial public offering price. All of the shares are being offered by Tandem. The shares are expected to begin trading tomorrow, November 14, 2013, on the NASDAQ Global Market under the ticker symbol “TNDM.” The offering is expected to close on November 19, 2013, pending customary closing conditions.
BofA Merrill Lynch and Piper Jaffray are acting as joint book-running managers for the offering. Deutsche Bank Securities and Stifel are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (SEC) on November 13, 2013. When available, copies of the final prospectus may be obtained from: BofA Merrill Lynch, 222 Broadway, New York, NY 10038 Attention: Prospectus Department, by email at dg.Prospectus_Requests@baml.com; or Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or by email at email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company manufactures and sells the t:slim Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, and the first and only insulin pump with a high resolution, color touch screen. Tandem is based in San Diego, California.